CASE STUDY



Jennifer Hoover, chief scientist of the Infectious Disease Therapy Area Unit at GlaxoSmithKline, used JoVE to reduce animal usage and save training time

In response to the demand from GSK researchers to learn from her lab, Mrs. Hoover sought a format that could illustrate the technical details of the model, and easily transfer this technique to other interested labs around the world.

GlaxoSmithKline Saves Two Months Training Its Pneumonia Model After Using JoVE

Challenge:

Mrs. Hoover's lab optimized, validated, and perfected a pneumonia model that her company researchers, contract research organizations, and academic labs have sought to learn over the years. Before publishing with JoVE the only way to teach the detailed model to other researchers was to host them on site; site visits required substantial coordination and paperwork for all parties involved.

Solution:

In response to the demand from her company researchers to learn from her lab, Mrs. Hoover sought a format that could illustrate the technical details of the model, and easily transfer this technique to other interested labs around the world. JoVE achieved both of these goals.

Results:

- With her publication in JoVE, Mrs. Hoover saves time by sharing the JoVE Video Article to explain the model, instead of hosting visits and filling out all the paperwork. This saves her at least two months for every training request, she said.
- With the publication she has been able to honor GSK's mission in reducing the number of animals required for learning and practicing a new technique.
- Mrs. Hoover used her JoVE video to present at a U.S. FDA Advisory Committee meeting and a workshop sponsored by National Institute of Allergy and Infectious Disease (NIAID).
- The pneumonia model has been viewed nearly 1,000 times in 24 different countries since it was published in January 2017.

"By providing explicit 'how to' instructions and a video demo, it exemplified GSK's commitment to the 3 Rs of animal research: reduce, replace and refine."

- Jen Hoover, GlaxoSmithKline